Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event.
There has been no literature which reports a case of interstitial lung disease associated with sorafenib. However, a recent post-marketing survey in Japan revealed that interstitial pneumonia occurred in 4 among approximately 2 000 Japanese patients treated with sorafenib. In this article, we describe a Japanese patient with severe interstitial pneumonia probably caused by sorafenib treatment for metastatic renal cell carcinoma. Oncologists supervising future clinical trials for lung cancer should be alert to the fact that sorafenib can potentially induce serious interstitial lung disease, although this might depend on racial differences.
Ide
Shotaro
S
Division of Respiratory Medicine, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan.
Soda
Hiroshi
H
Hakariya
Tomoaki
T
Takemoto
Shinnosuke
S
Ishimoto
Hiroshi
H
Tomari
Shinya
S
Sawai
Toyomitsu
T
Nagashima
Seiji
S
Furukawa
Masataka
M
Nakamura
Yoichi
Y
Kohno
Shigeru
S
D000970:Antineoplastic Agents / Q000009:adverse effects*; D044466:Asian People; D001557:Benzenesulfonates / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000556:secondary; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000503:physiopathology; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib